FRANKLIN LAKES, N.J., Oct. 22, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Carrie L. Byington has been appointed to the company’s board of directors, bringing the total number of directors to 13. Byington, 58, is executive vice president and head of University of California Health (UCH), where she... Read more
FRANKLIN LAKES, N.J., Aug. 11, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new benchtop cell analyzer that brings sophisticated flow cytometry capabilities to laboratories of all sizes. The new BD FACSymphony™ A1 Cell Analyzer is a fluorescence-activated cell analyzer that offers advanced... Read more
FRANKLIN LAKES, N.J., Aug. 5, 2021 /PRNewswire/ — Third fiscal quarter revenues of $4.9 billion grew 26.9% on a reported basis. On a currency-neutral basis, revenues increased 22.0%. BD’s COVID-19 testing revenues were $300 million, including BD Veritor™ Plus System revenues of $212 million. Third fiscal quarter GAAP diluted earnings per share (EPS) increased 77.3%... Read more
FRANKLIN LAKES, N.J., July 7, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of a new bdbiosciences.com web and eCommerce site, an entirely “reimagined” digital marketplace designed to provide an enhanced online purchasing experience for users and their procurement teams. The new BD... Read more
FRANKLIN LAKES, N.J., May 6, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.9 billion for the second fiscal quarter ended March 31, 2021. This represents an increase of 15.4% over the prior-year period on a reported basis and was driven by the contribution of... Read more
FRANKLIN LAKES, N.J., Feb. 4, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter ended December 31, 2020. This represents an increase of 25.8% over the prior-year period on a reported basis and was primarily driven by the... Read more
Polen to Succeed Vince Forlenza Effective April 28 FRANKLIN LAKES, N.J., Jan. 26, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will assume additional responsibility as chairman of the BD board of directors, effective April 28, 2021. Polen will succeed Vincent A. Forlenza, who... Read more
FRANKLIN LAKES, N.J., Jan. 12, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal quarter ended Dec. 31, 2020. “We have entered fiscal 2021 with strong momentum and now expect to deliver fiscal 2021 revenues toward the high-end of... Read more
FRANKLIN LAKES, N.J., Dec. 16, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling more than 1 billion injection devices to support global COVID-19 vaccination planning efforts. This milestone reflects commitments from governments across the world,... Read more
FRANKLIN LAKES, N.J., Nov. 5, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.784 billion for the fourth fiscal quarter ended September 30, 2020. This represents an increase of 4.4% over the prior-year period on both a reported and currency-neutral basis. “I’m extremely proud... Read more